New approaches to the therapy of various tumors based on peptide analogues

Hormone and Metabolic Research

Volumn 40, Issue 5, 2008, Pages 315-322

  Schally, A V ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer treatment; Cytotoxic analogues; GH RH antagonists; LH RH analogues; Targeted

Indexed keywords

2 PYRROLINODOXORUBICIN; AN 215; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BUSERELIN; CETRORELIX; CYTOTOXIC AGENT; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; DOXORUBICIN; GASTRIN RELEASING PEPTIDE; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; GONADOTROPIN ANTAGONIST; GOSERELIN; LEUPRORELIN; OCTREOTIDE; PENTETREOTIDE; PEPTIDE DERIVATIVE; PROTIRELIN; RC 3095; RC 3940 II; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; TRIPTORELIN; UNINDEXED DRUG; VAPREOTIDE;

ADVANCED CANCER; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; ENDOMETRIOSIS; ENDOMETRIUM CANCER; GONAD; HORMONE INHIBITION; HORMONE STRUCTURE; HUMAN; HYPOPHYSIS; KIDNEY CARCINOMA; LUNG CANCER; LYMPHOMA; MELANOMA; METASTASIS; MYOMA; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOLOGY; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SINGLE DRUG DOSE; STOMACH CANCER; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; NEOPLASMS; PEPTIDE HORMONES; PEPTIDES; SWINE;

SUIDAE;

EID: 45549089546     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1073142     Document Type: Review

References (82)

1. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001; 22: 248-291
2. th Edition. Hamilton, Ontario: B. C. Dekker Publishers 2006; 802-816
3. Schally AV. Aspects of hypothalamic regulation of the pituitary gland. Science 1978; 202: 18-28
4. Green JD, Harris GW. The neurovascular link between the neurohypophysis and adenohypophysis. J Endocrinol 1947; 5: 136-147
5. Saffran M, Schally AV. The release of corticotrophin by anterior pituitary tissue in vitro. Can J Biochem Physiol 1955; 33: 408-415
6. Schally AV, Bowers CY, Redding TW, Barrett JF. Isolation of thyrotropin releasing factor (TRF) from porcine hypothalamus. Biochem Biophys Res Commun 1966; 25: 165-169
7. Boler J, Enzmann F, Folkers K, Bowers CY, Schally AV. The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidine-proline amide. Biochem Biophys Res Commun 1969; 37: 705-710
8. Anderson MS, Bowers CY, Kastin A, Schalch DS, Schally AV, Snyder PJ, Utiger RD, Wilber JF, Wise AJ. Synthetic thyrotropin releasing hormone (TRH): A potent stimulator of thyrotropin secretion in man. N Engl J Med 1971; 285: 1279-1283
9. Kastin AJ, Schally AV, Gual C, Midgley Jr AR, Bowers CY, Diaz-Infante Jr A. Stimulation of LH release in men and women by LH-Releasing hormone purified from porcine hypothalami. J Clin Endocrinol Metab 1969; 29: 1040-1050
10. Schally AV, Arimura A, Baba Y, Nair RMG, Matsuo H, Redding TW, Debeljuk L, White WF. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 1971; 43: 393-399
11. Schally AV, Nair RMG, Redding TW, Arimura A. Isolation of the LH and FSH-releasing hormone from porcine hypothalami. J Biol Chem 1971; 246: 7230-7236
12. Matsuo H, Baba Y, Nair RMG, Arimura A, Schally AV. Structure of the porcine LH- and FSH-releasing hormone I, the proposed amino acid sequence. Biochem Biophys Res Commun 1971; 43: 1334-1339
13. Matsuo H, Arimura A, Nair RMG, Schally AV. Synthesis of the porcine LH- and FSH-releasing hormone by the solid-phase method. Biochem Biophys Res Commun 1971; 45: 822-827
14. Schally AV, Arimura A, Kastin AJ, Matsuo H, Baba Y, Redding TW, Nair RMG, Debeljuk L, White WF. The gonadotropins-releasing hormone: One polypeptide regulates the secretion of luteinizing and follicle-stimulating hormone. Science 1971; 173: 1036-1038
15. Schally AV, Kastin AJ, Arimura A. Hypothalamic FSH and LH-regulating hormone: structure, physiology and clinical studies. Fertil Steril 1971; 22: 703-721
16. Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev 1986; 7: 44-66
17. Hall R, Besser GM, Schally AV, Coy DH, Evered D, Goldie DJ, Kastin AJ, MacNeilly AS, Mortimer CH, Phenekos C, Turnbridge WMG, Weightman D. Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet 1973; ii: 581-584
18. Redding TW, Schally AV. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp-6LH-RH. Proc Natl Acad Sci USA 1981; 78: 6509-6512
19. Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas A, Comaru-Schally AM, Schally AV. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 1982; 79: 1658-1662
20. Redding TW, Schally AV, Tice TR, Meyers WE. Long acting delivery system for peptides: Inhibition of rat prostate tumors by controlled release of (D-Trp-6) luteinizing hormone-releasing hormone from injectable microcapsules. Proc Natl Acad Sci USA 1984; 81: 5845-5848
21. Schally AV. Luteinizing hormone releasing-hormone analogues: Their impact on the control of tumorigenesis. Peptides 1999; 20: 1247-1262
22. Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, Fuentes GM, Cardenas-Carnejo I, Graef-Sanchez A, Comaru-Schally AM, Schally AV. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 1994; 24: 84-92
23. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999; 141: 1-14
24. Ehrlich P. The relationship existing between chemical constitution, distribution, and pharmacological action. In: Himmelweite F, Marquardt M, Dale H (Eds). The Collected Papers of Paul Ehrlich. New York: Pergamon 1956; 596-618
25. Halmos G, Arenciba JM, Schally AV, Davis R, Bostwick DG. High incidence of receptors for luteinizing hormone-releasing hormone (LH-RH) and LH-RH receptor gene expression in human prostate cancers. J Urol 2000; 163: 623-629
26. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004; 15: 300-310
27. Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, Zarandi M, Groot K, Miyazaki M, Jungwirth A, Horvath J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxoruvicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996; 93: 7269-7273
28. Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analog AN-152 in androgen sensitive and insensitive prostate cancers. Clin Cancer Res 2003; 9: 4505-4513
29. Plonowski A, Schally AV, Nagy A, Groot K, Krupa M, Navone NM, Logothetis C. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett 2002; 176: 57-63
30. Stangelberger A, Schally AV, Nagy A, Szepeshazi K, Kanashiro CA, Halmos G. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207. Prostate 2006; 66: 200-210
31. Fekete M, Wittliff JL, Schally AV. Characteristics and distribution of receptors for D-Trp-6luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989; 3: 137-147
32. Chatzistamou I, Schally AV, Nagy A, Armatis P, Szepeshazi K, Halmos G. Effective treatment of metastatic MDA-MD-435 human estrogen independent breast carcinomas with a targeted cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. Clin Cancer Res 2000; 6: 4158-4165
33. Kahan Z, Nagy A, Schally AV, Halmos G, Arencibia JM, Groot K. Complete regression of MX- I human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. Cancer 1999; 85: 2608-2615
34. Bajo AM, Schally AV, Halmos G, Nagy A. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res 2003; 9: 3742-3748
35. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, Groot K, Armatis P. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer Inst 1997; 89: 1803-1809
36. Arencibia JM, Bajo AM, Schally AV, Krupa M, Chatzistamou I, Nagy A. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Anti Cancer Drugs 2002; 13: 949-956
37. Miyazaki M, Schally AV, Nagy A, Lamharzi N, Halmos G, Szepeshazi K, Armatis P. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. Am J Obstet Gynecol 1999; 180: 1095-1103
38. Engel JB, Keller G, Schally AV, Nagy A, Chism DD, Halmos G. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207. Fertil Steril 2005; 83: 1125-1133
39. Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G, Engel JB. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. Eur J Cancer 2005; 41: 2196-2202
40. Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Westphal G, Halmos G, Engel JB. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue. Cancer Res 2005; 65: 5857-5863
41. Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G, Engel JB. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues. Clin Cancer Res 2005; 11: 5549-5557
42. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-79
43. Schally AV, Dupont A, Arimura A, Redding TW, Nishi N, Linthicum GL, Schlesinger DH. Isolation and structure of growth hormone-release inhibiting hormone (somatostatin) from porcine hypothalami. Biochemistry 1976; 15: 509-514
44. Schally AV, Huang WY, Chang RCC, Arimura A, Redding TW, Millar RP, Hunkapiller MW, Hood LE. Isolation and structure of pro-somatostatin: A putative somatostatin precursor from pig hypothalamus. Proc Natl Acad Sci USA 1980; 77: 4489-4493
45. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133-1140
46. Cai RZ, Szoke B, Lu R, Fu D, Redding TW, Schally AV. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci USA 1986; 83: 1896-1900
47. 3)octreotide: The Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993; 20: 716-731
48. Nagy A, Schally AV, Halmos G, Armatis P, Cai R-Z, Csernus V, Kovacs M, Koppan M, Szepeshazi K, Kahn Z. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative 2- pyrrolinodoxonubicin. Proc Natl Acad Sci USA 1988; 95: 1794-1799
49. Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res 1999; 59: 1947-1953
50. Plonowski A, Schally AV, Nagy A, Sun B, Halmos G. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. Int J Oncology 2002; 20: 397-402
51. Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A. Effective treatment of experimental models of androgen-sensitive and androgen-independent prostate cancer metastatic to the bone with targeted cytotoxic somatostatin analog AN-238. J Urol 2004; 171: 911-915
52. Kahan Z, Nagy A, Schally AV, Hebert F, Sun B, Groot K, Halmos G. Inhibition of growth of MX- I, MCF-7, MIII and MDA-MB-23I human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. Int J Cancer 1999; 82: 592-598
53. Plonowski A, Schally AV, Koppan M, Nagy A, Arencibia JM, Csernus B, Halmos G. Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238. Cancer 2001; 92: 1168-1176
54. Engel JB, Schally AV, Halmos G, Baker B, Nagy A, Keller G. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Cancer 2005; 104: 1312-1321
55. Plonowski A, Schally AV, Nagy A, Kiaris H, Hebert F, Halmos G. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analog of somatostatin AN-238. Cancer Res 2000; 60: 2996-3001
56. Kiaris H, Schally AV, Nagy A, Sun B, Szepeshazi K, Halmos G. Regression of U-87MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. Clin Cancer Res 2000; 6: 709-717
57. Kiaris H, Schally AV, Nagy A, Szepeshazi K, Hebert F, Halmos G. A targeted cytotoxic somatostatin (SST) analogue AN-238 inhibits the growth of H-69 small cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. Eur J Cancer 2001; 37: 620-628
58. Szereday Z, Schally AV, Szepeshazi K, Bajo AM, Hebert F, Halmos G, Nagy A. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, an-238. Int J Oncol 2003; 22: 1141-1146
59. Szepeshazi K, Schally AV, Halmos G, Sun B, Hebert F, Csernus B, Nagy A. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancer. Clin Cancer Res 2001; 7: 2854-2861
60. Szepeshazi K, Schally AV, Halmos G, Armatis P, Hebert F, Sun B, Feil A, Kiaris H, Nagy A. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. Cancer Res 2002; 62: 781-788
61. Szepeshazi K, Schally AV, Nagy A, Wagner BW, Bajo AM, Halmos G. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer 2003; 98: 1401-1410
62. Keller G, Engel JB, Schally AV, Nagy A, Hammann B, Halmos G. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238. Int J Cancer 2005; 114: 831-835
63. Keller G, Schally AV, Nagy A, Baker B, Halmos G, Engel JB. Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multidrug resistance proteins. Int J Oncol 2006; 28: 1507-1513
64. 2 or its derivatives. Proc Natl Acad Sci USA 1994; 91: 12664-12668
65. Nagy A, Armatis P, Cai R-Z, Szepeshazi K, Halmos G, Schally AV. Design, synthesis and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci USA 1997; 94: 652-656
66. Schally AV, Varga JL. Antagonistic analogs of growth hormone-releasing hormone: New potential antitumor agents. Trends Endocrinol Metab 1999; 10: 383-391
67. Schally AV, Varga JL. Antagonists of growth hormone-releasing hormone. Comb Chem High Throughput Screen 2006; 9: 163-170
68. Varga JL, Schally AV. Analogues of growth hormone-releasing hormone (GH-RH) in cancer. In: Kastin A (Ed). Handbook of Peptides. London: Elsevier/Academic Press 2006; 483-489
69. Szepeshazi K, Schally AV, Groot K, Armatis P, Hebert F, Halmos G. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumors. Eur J Cancer 2000; 36: 128-136
70. Szepeshazi K, Schally AV, Groot K, Armatis P, Halmos G, Hebert F, Szende B, Varga JL, Zarandi M. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer 2000; 82: 1724-1731
71. Plonowski A, Schally AV, Krupa A, Hebert F, Groot K, Varga JL. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone; lack of correlation with the levels of serum IGF-I and expression of IGF-II and vascular endothelial growth factor. Prostate 2002; 52: 173-182
72. Kahan Z, Varga JL, Schally AV, Rekasi Z, Armatis P, Chatzistamou I, Czompoly T, Halmos G. Antagonists of growth hormone Releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Res Treat 2000; 60: 71-79
73. Halmos G, Schally AV, Varga JL, Plonowski A, Rekasi Z, Czompoly T. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc Natl Acad Sci USA 2000; 12: 10555-10560
74. Kiaris H, Schally AV, Varga JL. Antagonists of growth hotmone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. Neoplasia 2000; 2: 242-250
75. Kiaris H, Schally AV, Varga JL, Groot K, Armatis P. Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci USA 1999; 96: 14894-14898
76. Engel JB, Keller G, Schally AV, Toller GL, Groot K, Havt A, Armatis P, Zarandi M, Varga JL, Halmos G. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. J Clin Endocrinol Metab 2005; 90: 3614-3621
77. Halmos G, Schally AV, Czompoly T, Krupa M, Varga JL, Rekasi Z. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. J Clin Endocrinol Metab 2002; 87: 4707-4714
78. Busto R, Schally AV, Varga JL, Garcia-Fernandez MO, Groot K, Armatis P, Szepeshazi K. The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci USA 2002; 99: 11866-11871
79. Kanashiro CA, Schally AV, Varga JL, Havt A, Hammann BD, Groot K, Halmos G, Zarandi M. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. Int J Oncology 2007; 30: 1019-1028
80. Keller G, Schally AV, Groot K, Toller GL, Havt A, Kostet F, Armatis P, Halmos G, Zarandi M, Varga JL, Engel JB. Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA 2005; 102: 10628-10633
81. Rekasi Z, Czompoly, Schally AV, Halmos G. Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci USA 2000; 12: 10561-10566
82. Havt A, Schally AV, Halmos G, Varga JL, Toller GL, Horvath JE, Szepeshazi K, Koster F, Kovitz K, Groot K, Zarandi M, Kanashiro CA. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci USA 2005; 102: 17424-17429